WhiteLab Genomics Raises $26 Million in Series B Funding
WhiteLab Genomics, a Paris-based company integrating artificial intelligence with biological sciences to optimize drug design in genomic medicine, has successfully raised $26 million in a Series B funding round. This round, which took place on October 6, 2026, was led by AVP, with participation from investors Yaday Health, Blast Club, Omnes Capital, and the Debiopharm Innovation Fund.
Company Background and Leadership
Founded in 2019, WhiteLab Genomics is spearheaded by CEO and co-founder David Del Bourgo, alongside co-founder and Chief of Staff Lucia Cinque. The company collaborates with notable organizations like Sanofi and Cytiva, as well as leading academic institutions, to advance the development of genomic medicines. Del Bourgo commented on the funding, saying: "AI can help us design better genomic medicines, but what ultimately matters is whether those designs work in living systems."
Strategic Use of Funds
The newly acquired funds will be utilized to accelerate WhiteLab Genomics' in vivo testing programs, focusing on both viral and non-viral delivery technologies and programmable genetic payloads. Additionally, the company plans to expand its business operations across North America, Europe, and Asia. This expansion aims to build a comprehensive portfolio of experimentally tested biological assets, which can be developed independently or in collaboration with biopharmaceutical partners.
Looking Ahead
With this Series B funding, WhiteLab Genomics is well-positioned to enhance its AI-driven platform further, potentially leading to significant advancements in the field of genomic medicine. The company's efforts to optimize drug design for increased safety and efficacy continue to gain momentum as it broadens its international reach.